EFFECT OF SPERMININE AND ITS COMBINATION WITH SPERMINOXIDASE INHIBITORS ON THE PROFILE OF POLYAMINE AND SURVIVAL OF HUMAN PROSTATE CANCER CELLS


O.O. Klenov, S.P. Zaletok, Yu.V. Yanish, І.О. Sumnikova
R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, NAS of Ukraine, Kyiv, Ukraine

DOI: https://doi.org/10.15407/oncology.2024.02.112

 

Summary. Aim: to investigate the effect of spermine (Spn) and spermine oxidase inhibitors (SMO) and their effect in combination on the polyamine profile in human PCa cell lines and to compare the nature of polyamine changes with tumor cell viability. Object and methods: the study was performed on cell cultures of hormone-sensitive (LNCaP) and hormone-resistant (DU-145) cell lines. The profile of polyamines in tumor cells and the activities of spermine oxidase and polyamine oxidase (PAO) were determined by high-performance liquid chromatography. Results: the addition of Spn to the culture medium causes a significant accumulation of this polyamine in cells, a decrease in putrescine (Put) and spermidine (Spd). The use of SMO inhibitors (chlorhexidine and MDL-72527) is accompanied by a decrease in Spd levels and accumulation of acetylated spermidine (AcSpd). The use of Spn leads to a decrease in the proliferation rate — the molar ratio of spermidine/spermine (Spd/Spn). Particularly low values of the Spd/Spn ratio were observed when spermine was used in combination with SMO inhibitors. When Spn was used in combination with SMO inhibitors, the lowest cell viability rates were also observed, indicating a more effective inhibition of cell growth with the combined use of these factors compared to their use separately, even in significantly higher concentrations. The use of chlorhexidine and chlorhexidine together with spermine led to a decrease in the activity of SMO and PAO. Conclusions: the use of spermine and spermine in combination with SMO inhibitors leads to changes in the polyamine profile in tumor cells characteristic of growth inhibition (decrease in Spd, Put and increase in Spn) and a decrease in the molar ratio Spd/Spn. These changes are accompanied by a decrease in the survival of cells of hormone-sensitive (LNCaP) and hormone-resistant (DU-145) human prostate cancer lines. The obtained results show the prospects for further study of spermine and its combination with SMO inhibitors as potential agents for the treatment of prostate cancer.

 

References

  1. Pegg Functions of polyamines in mammals. J Biol Chem 2016; 291 (29): 14904–12. https://doi.org/10.1074/jbc.R116. 731661.
  2. Igarashi K, Kashiwagi K. The functional role of polyamines in eukaryotic c Int J Biochem Cell Biol 2019; 109: 104–15. https://doi.org/10.1016/j.biocel.2018.12.012
  3. Zahedi K, Barone S, Soleimani Polyamines and their metabolism: From the maintenance of physiological homeostasis to the mediation of disease. Med Sci (Basel) 2022; 10 (3):  38–56.  https://doi.org/10.3390/medsci10030038.
  4. Stolarska E, Paluch-Lubawa E, Grabsztunowicz M, et al. Polyamines as universal bioregulators across kingdoms and their role in cellular longevity and Critical Reviews in Plant Sciences 2023; 42 (6): 364–84. https://doi.org/10.1080/07352689.2023.2247886.
  5. Sagar NA, Tarafdar S, Agarwal S, et al. Polyamines: Func- tions, metabolism, and role in human disease management. Medical Sci 2021; 9 (2): https://doi.org/10.3390/medsci 9020044.
  6. Xuan M, Gu X. Li J, et al. Polyamines: their significance for maintaining health and contributing to diseases. Cell Commun Signal 2023; 21 (1): 348. https://doi.org/10.1186/s12964-023-01373-0.
  7. Li J, Meng Y, Wu X, et al. Polyamines and related signaling pathways in Cancer Cell Int 2020; 20 (1): 539. https://doi.org/10.1186/s12935-020-01545-9.
  8. Berdinskikh NK. Zaletok SP. Poliaminy i opukholevyi Kiyv: Nauk. dumka, 1987. 140 p. (in Russian).
  9. Zaletok The role of polyamines in carcinogenesis and tumor growth. In: Onkolohiya. Lektsiyi. Chekhun VF (eds). K: Zdorov’ya Ukrayiny, 2010: 354–70. (in Ukrainian).
  10. Aff onti HC, Rowsam AM, Pellerite AJ, et al. Pharmacological polyamine catabolism upregulation with methionine salvage pathway inhibition as an effective prostate cancer Nat Commun 2020; 11 (1): 52–67. https://doi.org/10.1038/s41467-019-13950-4.
  11. Tummala R, Diegelman P, Hector S, et al. Combination ef- fects of platinum drugs and N1, N11 diethylnorspermine on spermidine/spermine N1-acetyltransferase, polyamines and growth inhibition in A2780 human ovarian carcinoma cells and their oxaliplatin and cisplatin-resistant variants. Cancer Chemother Pharmacol 2011; 67 (2): 401–14. https://doi.org/10.1007/s00280-010-1334-9.
  12. Xie Y, Murray-Stewart T, Wang Y, et al. Self-immolative nanoparticles for simultaneous delivery of microRNA and targeting of polyamine metabolism in combination cancer J Control Release 2017; 246: 110–9. https://doi.org/10.1016/j.jconrel.2016.12.017.
  13. Hayes CS, Shicora AC, Keough MP, et al. Polyamine-blo- cking therapy reverses immunosuppression in the tumor mi- Cancer Immunol Res 2014; 2 (3): Р. 274– 85. https://doi.org/10.1158/2326-6066.CIR-13-0120-T.
  14. Alexander ET, Minton A, Peters MC, et al. A novel polyamine blockade therapy activates an antitumor immune response. Oncotarget 2017; 8 (48): 84140–52. https://doi.org/10.18632/oncotarget.20493.
  1. Lian J, Liang Y, Zhang H, et al. The role of polyamine metabolism in remodeling immune responses and blocking therapy within the tumor immune microenvironment. Front Immunol 2022; 13: 9122 https://doi.org/10.3389/fi12279.
  2. Cervelli M, Polticelli F, Fiorucci L, et al. Inhibition of acetylpolyamine and spermine oxidases by the polyamine analogue c J Enzyme Inhib Med Chem 2013: 28 (3): 463–7. https://doi.org/10.3109/14756366.2011.650691.
  3. Sun L, Yang J, Qin Y, et al. Discovery and antitumor evaluation of novel inhibitors of spermine J Enz Inhib Med Chem 2019; 34 (1): 1140–51. https://doi.org/10.1080/14756366.2019.1621863.
  4. Furbish AB, Alford AS, Burger P, et al. Identification and characterization of novel small-molecule СМО inhibi- Med Sci 2022; 10: 47. https://doi.org/10.3390/medsci10030047.
  5. Li X, Li F, Ye Fi, et al. Spermine is a natural suppressor of AR signaling in castration-resistant prostate Cell Reports 2023; 42 (7): 112798. https://doi.org/10.1016/j.celrep.2023.112798/1.
  6. James ND, Tannock I, N’Dow J, et al. The Lancet Commission on prostate cancer: planning for the surge in Lancet 2024; 403 (10437): 1683–722. https://doi.org/10.1016/S0140-6736(24)00651-2.
  7. Goodwin AC, Jadallah S, Toubaji A, et al. Increased sper- mine oxidase expression in human prostate cancer and prostatic intraepithelial neoplasia Prostate 2008; 68 (7): 766–72. https://doi.org/10.1002/pros.20735.
  8. Peng Q, Wong CY-P, Cheuk IW-y, et al. The emerging clinical role of spermine in prostate Int J Mol Sci 2021; 22 (9): 4382. https://doi.org/10.3390/ij94382/3.
  9. Zaletok SP, Klenov OO, Bentrad VV, et al. Polyamines as new potential biomarkers for differential diagnosis of prostate cancer and estimation of its Exp Oncol 2022; 44 (2): 148–54. https://doi.org/10.32471/exp-oncology.2312-8852.vol-44-no-2.17758.
  10. Giskdegård GF, Bertilsson H, Selnæs KM, et al. Spermine and citrate as metabolic biomarkers for assessing prostate cancer PLoS One. 2013; 8 (4): e62375. https://doi.org/10.1371/journal.pone.0062375.
  11. Basharat M, Payne GS, Morgan VA, et al. TE=32 ms vs TE=100 ms echo-time (1)H-magnetic resonance spectroscopy in prostate cancer: Tumor metabolite depiction and absolute concentrations in tumors and adjacent tissues. J Magn Reson Imaging 2015; 42: 1086–93. https://doi.org/10.1002/jmri.24875.
  12. Zaletok SP, Klenov OO, Bentrad VV, et al. Polyamines as new potential biomarkers for differential diagnosis of prostate cancer and estimation of its Exp Oncol 2022; 44 (2): 148–54. https://doi.org/10.32471/exp-oncology.2312-8852.vol-44-no-2.17758.
  13. Harrison GA. Spermine in human Biochem J 1931; 25 (6): 1885–1892. https://doi.org/10.1042/bj0251885.
  1. Harrison GA. CLIII. The approximate determination of spermine in single human Biochem J 1933; 27 (4): 1152–6. https://doi.org/10.1042/bj0271152.
  2. Smith R, Litwin M, Lu Y, Zetter Identification of an endogenous inhibitor of prostate carcinoma cell growth. Nature Med 1995; 1: 1040–5. https://doi.org/10.1038/nm1095-1040.
  3. Koike C, Chao DT, Zetter Sensitivity to polyamine — induced growth arrest correlates with antizyme induction in prostate carcinoma cells. Cancer Res 1999; 59: 6109–12. http://cancerres.aacrjournals.org/content/59/24/6109.
  1. Gerbaut Determination of erythrocytic polyamines by reversed-phase liquid chromatography. Clin Chem 1991; 37: 2117–20.
  2. Halline АМ., Brasitus TA. Reversed-phase high-performance liquid chromatographic method for the measurement of polyamine oxidase activity. J Chromatogr 1990; 533: 187– 9  https://doi.org/10.1016/S0378-4347(00)82201-X.
  3. Lakin GF. M: Higher School, 1990. 352 p. (in Russian).
  4. Yanish YuV, Prylutskyi MP, Zaletok The influence of spermine on the survival and electrokinetic characteristics of human prostate cancer LNCaP cell line. Oncology 2022; 24 (3): 163–8. doi: https://doi.org/10.32471/oncology.2663-7928.t-24-3-2022-g.10728 (in Ukranian).
  1. Prylutskyi MP, Voronina OK, Zaletok The influence of spermine and aminoguanidine on the morphofunc- tional characteristics of human prostate cancer cell line LNCaP. Oncology 2023; 25 (1): 45–52. doi: https://doi.org/10.15407/oncology.2023.01.024 (in Ukranian).

 


No comments » Add comment